Short answer
Ardent Health, Inc. (ARDT) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). CEO transition effective June 2, 2026: Dave Caspers succeeds Martin J. Bonick and joins the Board.
Ardent Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO transition effective June 2, 2026: Dave Caspers succeeds Martin J. Bonick and joins the Board
- Caspers brings prior COO experience since March 2025 and healthcare operations leadership at Walmart Health and Banner Health
- Employment term through May 31, 2029, with $900,000 base salary and 105% target bonus opportunity for 2026
- New equity incentives total $3,000,000 target value: $1,050,000 RSUs and $1,950,000 performance-based RSUs
- Severance protection equals 2x compensation generally or 3x after qualifying change-in-control termination; Bonick separation terms remain pending
Item 7.01 · Regulation FD Disclosure
- Press release issued June 2, 2026 regarding a leadership transition
- Exhibit 99.1 contains the substantive announcement and is incorporated by reference
- Leadership change may affect operating priorities, execution, and investor confidence
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Ardent Health, Inc. 8-K filings
Get the next ARDT 8-K as it lands
Follow ARDT for push alerts, or ask the research agent what this filing means.